| Collaboration Partner | GlaxoSmithKline |
| Development Status | ANDA Under FDA Review |
| Therapeutic Category | Cardiovascular, Pain |
| Target Indication(s) | Hypertension, Migraine |
| Eurand Technology Platform(s) | Diffucaps® - Customized Drug Release technology |
EUR-1000 was designed to be an AB-rated generic product to Inderal LA, a long-acting formulation of propranolol that is indicated for the treatment of hypertension and migraines.
Because the patents related to Inderal LA have expired, Eurand’s new formulation has the opportunity to capture share of long-acting propranolol market by offering an AB-rated generic formulation.